RM-END / Endocrine and peptide-hormone analogs
Vosoritide
Also known as: Voxzogo · BMN 111
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Vosoritide is a modified C-type natriuretic peptide analog. Its exact sequence modifications and kit presentation are part of the identity record.
Evidence position
The regulated injection kit and human evidence support Grade A for the labeled product.
What the record does not establish
The product record does not authenticate a separately sourced peptide or make another sequence or formulation equivalent.
Sources
- 01Vosoritide compound recordPubChem
- Shows
- Registry identity, structure, formula and synonyms for vosoritide
- Does not show
- Does not establish a kit formulation, approval transfer or lot quality
- 02Voxzogo prescribing informationDailyMed / U.S. National Library of Medicine
- Shows
- Current U.S. label for defined vosoritide injection kits
- Does not show
- Does not qualify another peptide analog, strength, kit or source
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Vosoritide
- CID
- 119058036
- Formula
- C176H290N56O51S3
- Mass
- 4103
PUBMED / FOUND RECORDS
- Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial.Lancet (London, England) / 2020 Sep 5PMID 32891212 / DOI 10.1016/S0140-6736(20)31541-5
- Vosoritide (Voxzogo) for Achondroplasia: A Review of Clinical and Real-World Evidence.Cureus / 2025 JulPMID 40821249 / DOI 10.7759/cureus.87983
- Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.The Lancet. Child & adolescent health / 2024 JanPMID 37984383 / DOI 10.1016/S2352-4642(23)00265-1
- Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study.Genetics in medicine : official journal of the American College of Medical Genetics / 2021 DecPMID 34341520 / DOI 10.1038/s41436-021-01287-7
- Vosoritide treatment for children with hypochondroplasia: a phase 2 trial.EClinicalMedicine / 2024 MayPMID 38813446 / DOI 10.1016/j.eclinm.2024.102591
CLINICALTRIALS.GOV / FOUND RECORDS
- Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VIACTIVE_NOT_RECRUITING / PHASE1, PHASE2 / University of California, San FranciscoNCT05845749 / DIRECT intervention MATCH: Vosoritide
- A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)ACTIVE_NOT_RECRUITING / PHASE2 / BioMarin PharmaceuticalNCT02724228 / DIRECT intervention MATCH: Vosoritide
- A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With AchondroplasiaCOMPLETED / PHASE2 / BioMarin PharmaceuticalNCT02055157 / DIRECT intervention MATCH: Vosoritide
- A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 MonthsRECRUITING / PHASE2 / BioMarin PharmaceuticalNCT07126262 / DIRECT intervention MATCH: Vosoritide
- Interventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaACTIVE_NOT_RECRUITING / PHASE3 / BioMarin PharmaceuticalNCT06455059 / DIRECT intervention MATCH: Vosoritide